NASDAQ:OTIC - Otonomy Stock Price, Price Target & More

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Otonomy Inc (NASDAQ:OTIC) released its quarterly earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.46 million. Otonomy had a negative net margin of 6,316.88% and a negative return on equity of 58.60%. Otonomy's revenue for the quarter was down 1.1% compared to the same quarter last year. View Otonomy's Earnings History.

4 equities research analysts have issued twelve-month target prices for Otonomy's shares. Their forecasts range from $8.00 to $15.00. On average, they expect Otonomy's share price to reach $10.00 in the next year. This suggests a possible upside of 170.3% from the stock's current price. View Analyst Ratings for Otonomy.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Otonomy saw a decline in short interest in the month of June. As of June 29th, there was short interest totalling 727,991 shares, a decline of 44.9% from the June 15th total of 1,321,378 shares. Based on an average trading volume of 576,927 shares, the days-to-cover ratio is presently 1.3 days. Currently, 2.8% of the company's stock are sold short. View Otonomy's Current Options Chain.

Some companies that are related to Otonomy include Forty Seven (FTSV), Verrica Pharmaceuticals (VRCA), Dermira (DERM), Evelo Biosciences (EVLO), ZIOPHARM Oncology (ZIOP), Sinovac Biotech (SVA), Syros Pharmaceuticals (SYRS), Unum Therapeutics (UMRX), Achillion Pharmaceuticals (ACHN), American Brivision (Holding) (ABVC), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Savara (SVRA), Xeris Pharmaceuticals (XERS) and ProMetic Life Sciences (PFSCF).

Media headlines about OTIC stock have been trending somewhat positive on Thursday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Otonomy earned a news impact score of 0.13 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.84 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $3.70.

Otonomy has a market capitalization of $114.67 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]